Efficient Frontier of Immune Reset
Immune Reset necessarily requires synchronous deep B cell depletion of the peripheral, tissue and memory compartments as well as T cell modulation to prevent autoreactive B cell activation.
A Deceptively Simple Idea with Profound Implications
CD20 & CD40 are validated powerful upstream targets on pathologic B & APC engaging T cells
α-CD20 x
α-CD40 BsAb
Rational Antibody Engineering
Immune Reset
Requires Both Humoral & Cellular Immunomodulation
Co-Expression of CD20 & CD40 in pathogenic autoimmune B cells & APC presentation to T cells is High1
Safe by Design
α-CD20 x α-CD40 BsAb inverse mechanism to TCE by directly depleting CD20+ B cells & CD40+ APCs & indirectly inhibiting activation, without depletion of CD4+ and CD8+ T cells
Pipeline in a Platform
|
Therapy
|
Indications
|
Status
|
||
|---|---|---|---|---|
DFI 105 |
Monoclonal mAb† 𝛼-CD40
 |
Transplantation &
Multiple Sclerosis |
IND-Enabled
IND-Enabled |
DFI 105
|
DFI 205 |
Bivalent BsAb‡ 𝛼-CD20 x 𝛼-CD40
|
Autoimmunity (RA, SLE, Sjögren's,MS)
Multiple Sclerosis (RRMS, PPMS, Prevention) |
FIH H1 2026
FIH H2 2026 |
DFI 205
|
DFI 305 |
Trispecific TsAb# 𝛼-CD19 x 𝛼-CD20x𝛼-CD40
|
Oncology
|
2027
|
DFI 305
|
Antibody Legend
𝛼-CD20
𝛼-CD40
Intellectual Property
† DFI 105~2043 Composition of Matter
‡ DFI 205~2048 Composition of Matter
# DFI 305~2050 Composition of Matter
NB: Antibody graphics not representative of actual structure
α-CD20 x α-CD40 BsAb Efficacy PoC First-In-Human Clinical Trials
